CY1113253T1 - Δοσολογικο σχημα για τη θεραπευτικη αντιμετωπιση μιας τραυματικης εγκεφαλικης βλαβης με προγεστερονη - Google Patents

Δοσολογικο σχημα για τη θεραπευτικη αντιμετωπιση μιας τραυματικης εγκεφαλικης βλαβης με προγεστερονη

Info

Publication number
CY1113253T1
CY1113253T1 CY20121101012T CY121101012T CY1113253T1 CY 1113253 T1 CY1113253 T1 CY 1113253T1 CY 20121101012 T CY20121101012 T CY 20121101012T CY 121101012 T CY121101012 T CY 121101012T CY 1113253 T1 CY1113253 T1 CY 1113253T1
Authority
CY
Cyprus
Prior art keywords
progesterone
brain injury
traumatic brain
dosage regimen
therapeutic treatment
Prior art date
Application number
CY20121101012T
Other languages
English (en)
Inventor
Stuart W Hoffman
Arthur L Kellermann
Donald G Stein
David W Wright
Douglas W Lowery-North
Sarah Melissa Cutler
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of CY1113253T1 publication Critical patent/CY1113253T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Μέθοδοι θεραπευτικής αντιμετώπισης ενός ατόμου με τραυματική βλάβη του κεντρικού συστήματος, πιο συγκεκριμένα με μια τραυματική εγκεφαλική βλάβη. Οι μέθοδοι περιλαμβάνουν μια θεραπεία που αποτελείται από ένα σταθερό ή ένα δοσολογικό σχήμα δυο σταδίων χορήγησης προγεστερόνης. Σε μια μέθοδος, σε έναν ασθενή με την ανάγκη αυτού χορηγείται τουλάχιστον ένας κύκλος θεραπείας, που περιλαμβάνει τη χορήγηση ενός θεραπευτικά δραστικού ενδοφλέβιου δοσολογικού σχήματος προγεστερόνης. Το δοσολογικό σχήμα δυο σταδίων περιλαμβάνει μια πρώτη χρονική περίοδο, κατά την οποία χορηγείται στο άτομο μια υψηλότερη ωριαία δόση προγεστερόνης, ακολουθούμενη από μια δεύτερη χρονική περίοδο, κατά την οποία χορηγείται στον ασθενή μια χαμηλότερη ωριαία δόση προγεστερόνης.
CY20121101012T 2005-03-24 2012-10-25 Δοσολογικο σχημα για τη θεραπευτικη αντιμετωπιση μιας τραυματικης εγκεφαλικης βλαβης με προγεστερονη CY1113253T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66472805P 2005-03-24 2005-03-24
US72966305P 2005-10-24 2005-10-24
EP06748657A EP1868614B1 (en) 2005-03-24 2006-03-24 Dosage regimen for the treatment of a traumatic brain injury with progesterone

Publications (1)

Publication Number Publication Date
CY1113253T1 true CY1113253T1 (el) 2016-04-13

Family

ID=36987966

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111100496T CY1111478T1 (el) 2005-03-24 2011-05-20 Ενδειξη δοσολογιας προγεστερονης στην αντιμετωπιση τραυματικης εγκεφαλικης βλαβης
CY20121101012T CY1113253T1 (el) 2005-03-24 2012-10-25 Δοσολογικο σχημα για τη θεραπευτικη αντιμετωπιση μιας τραυματικης εγκεφαλικης βλαβης με προγεστερονη

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20111100496T CY1111478T1 (el) 2005-03-24 2011-05-20 Ενδειξη δοσολογιας προγεστερονης στην αντιμετωπιση τραυματικης εγκεφαλικης βλαβης

Country Status (16)

Country Link
US (4) US20090325920A1 (el)
EP (5) EP2494976A1 (el)
JP (5) JP5295755B2 (el)
AT (2) ATE499104T1 (el)
AU (2) AU2006226811B2 (el)
CA (2) CA2602950C (el)
CY (2) CY1111478T1 (el)
DE (1) DE602006020353D1 (el)
DK (2) DK1868614T3 (el)
ES (2) ES2428313T3 (el)
HK (3) HK1112579A1 (el)
HR (2) HRP20110198T1 (el)
PL (2) PL2030622T3 (el)
PT (2) PT2030622E (el)
RS (1) RS52471B (el)
WO (2) WO2006102596A2 (el)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5295755B2 (ja) 2005-03-24 2013-09-18 エモリー ユニバーシティー プロゲステロンによる外傷性脳損傷の治療のための投薬レジメン
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
EP2052724A1 (en) * 2007-10-26 2009-04-29 sanofi-aventis Use of norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC6 and TRPC7 ion channel
US9527881B2 (en) 2008-02-26 2016-12-27 Emory University Steroid analogues for neuroprotection
MX2011003015A (es) 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
US20110306579A1 (en) * 2009-01-30 2011-12-15 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US10987361B2 (en) 2010-02-08 2021-04-27 Shenzhen Evergreen Therapeutics Co., Ltd. Treating auto-immune and auto-inflammatory diseases
US10993879B2 (en) * 2010-02-08 2021-05-04 Shenzhen Evergreen Therapeutics Co., Ltd. Pulmonary delivery of progestogen
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
RU2016101363A (ru) 2010-02-08 2018-11-21 Прэари Фармасьютикалз, Ллк Способ лечения заболеваний, связанных с глюкокортикоидной нечувствительностью
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
EP2701721A4 (en) * 2011-04-27 2015-12-16 Univ Northwestern METHODS OF TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, AUTISM OR OTHER DISORDERS
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
PL2806877T3 (pl) * 2012-01-23 2020-06-01 Sage Therapeutics, Inc. Formulacje neuroaktywnego steroidu zawierające kompleks allopregnanolonu i eteru sulfobutylowego beta-cyklodekstryny
US20130210785A1 (en) 2012-02-15 2013-08-15 Emory University Progesterone analogs and uses related thereto
IN2014DN08088A (el) 2012-02-29 2015-05-01 Braun Melsungen Ag
RU2498826C1 (ru) * 2012-05-14 2013-11-20 Федеральное государственное бюджетное учреждение науки Комплексный научно-исследовательский институт им. Х.И. Ибрагимова Российской академии наук Способ лечения больных с черепно-мозговой травмой
EP3957309A1 (en) * 2012-08-21 2022-02-23 Sage Therapeutics, Inc. Preparation of a composition comprising allopregnanolone and sulfobutylether-beta-cyclodextrin
JP2016501876A (ja) 2012-11-30 2016-01-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ステロイドの抗痙攣活性
MX2015009773A (es) 2013-01-29 2016-08-05 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
WO2014120800A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
KR102410989B1 (ko) 2013-01-29 2022-06-17 앱티닉스 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
BR112015018095A2 (pt) 2013-01-29 2017-07-18 Naurex Inc moduladores de receptor nmda de espiro-lactama e usos dos mesmos
ES2935352T3 (es) 2013-01-29 2023-03-06 Aptinyx Inc Moduladores de receptores NMDA de espiro-lactama y sus usos
WO2015023593A1 (en) 2013-08-12 2015-02-19 Emory University Progesterone phosphate analogs and uses related thereto
US10231979B2 (en) * 2015-08-07 2019-03-19 Indiana University Research And Technology Corporation Modulation of inflammation using progesterone metabolites
MA43815A (fr) 2016-03-08 2021-04-07 Sage Therapeutics Inc Stéroïdes neuroactifs, compositions, et leurs utilisations
WO2017201283A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN109661398B (zh) 2016-08-01 2022-07-05 阿普廷伊克斯股份有限公司 螺-内酰胺和二-螺-内酰胺nmda受体调节剂及其用途
CA3031534C (en) 2016-08-01 2023-10-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
BR112019001768A2 (pt) 2016-08-01 2019-06-11 Aptinyx Inc moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
AU2017306164B2 (en) 2016-08-01 2021-10-21 Aptinyx Inc. Spiro-lactam NMDA modulators and methods of using same
ES2973283T3 (es) 2016-08-01 2024-06-19 Tenacia Biotechnology Hong Kong Co Ltd Moduladores de receptores de NMDA espirolactámicos y usos de los mismos
WO2019152687A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
CA3239142A1 (en) * 2021-12-02 2023-06-08 Mukesh Chatter Methods and uses of microbiome compositions, components, or metabolites for treating vagus nerve associated diseases, disorders, and conditions
WO2024059056A1 (en) * 2022-09-12 2024-03-21 Emory University Methods of managing traumatic brain injury

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5217085A (en) 1975-07-30 1977-02-08 Ono Pharmaceut Co Ltd Method of quantitative determination of free fatty acids in serum usin g fatty acid activating enzymes
US4404366A (en) * 1980-05-06 1983-09-13 Miles Laboratories, Inc. Beta-galactosyl-umbelliferone-labeled hapten conjugates
US4369250A (en) 1981-07-31 1983-01-18 Sherwood Medical Industries Inc. Fatty acid determination
USRE35517E (en) * 1987-08-25 1997-05-20 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
AU609927B2 (en) 1987-08-25 1991-05-09 Kelvin W. Gee Compositions and methods for alleviating stress, anxiety and seizure activity
US5512429A (en) 1989-09-19 1996-04-30 British Technology Group Limited Assay for enzyme activity
GB9105707D0 (en) 1991-03-18 1991-05-01 Wilton David C Assay
US5114388A (en) * 1991-07-26 1992-05-19 True Fitness Technology, Inc. Stair simulator exerciser with adjustable incline
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
ATE275957T1 (de) * 1993-01-19 2004-10-15 Endorech Inc Therapeutische verwendungen und verabreichungsysteme von dehydroepiandrosteron
DE4311870C2 (de) 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
WO1995005826A1 (en) * 1993-08-20 1995-03-02 Jackson Meyer B Method for regulating neuropeptide hormone secretion
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
US5837544A (en) * 1995-02-02 1998-11-17 Cell Genesys, Inc. Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
WO1996040043A2 (en) * 1995-06-06 1996-12-19 Cocensys, Inc. Neuroactive steroids of the androstane and pregnane series
DE69632569T2 (de) * 1995-06-09 2005-08-18 Euroceltique S.A. Formulierungen und verfahren für eine verlängerte lokalanästhesie
US5888996A (en) * 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
CA2256365A1 (en) 1996-05-22 1997-11-27 Diversified Pharmaceuticals, Inc. Compositions, methods and devices for the transdermal delivery of drugs
US5763492A (en) * 1996-10-01 1998-06-09 Duguesne University Of The Holy Ghost Methods for effecting memory enhancement mediated by non-steroidal sulfatase inhibitors
ATE227130T1 (de) 1997-05-02 2002-11-15 Wyeth Corp 5-alpha-pregnan-3-beta-ol-20-one 3-sulfate für di behandlung von tumoren und zns krankheiten
US6245757B1 (en) * 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6268223B1 (en) 1999-08-27 2001-07-31 Viatech Imagin, Llc Assay for detecting damage to the central nervous system
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
JP5295755B2 (ja) * 2005-03-24 2013-09-18 エモリー ユニバーシティー プロゲステロンによる外傷性脳損傷の治療のための投薬レジメン

Also Published As

Publication number Publication date
EP2431042A1 (en) 2012-03-21
DE602006020353D1 (de) 2011-04-07
AU2006226774A1 (en) 2006-09-28
HK1112581A1 (en) 2008-09-12
DK2030622T3 (da) 2011-05-02
US20120245133A1 (en) 2012-09-27
JP2011225629A (ja) 2011-11-10
CA2601715C (en) 2012-10-16
ES2428313T3 (es) 2013-11-07
PT1868614E (pt) 2012-11-23
WO2006102644A9 (en) 2006-11-23
ATE499104T1 (de) 2011-03-15
CA2602950C (en) 2012-10-30
RS52471B (en) 2013-02-28
JP2008534512A (ja) 2008-08-28
WO2006102596A3 (en) 2007-01-18
HRP20110198T1 (hr) 2011-04-30
WO2006102596A2 (en) 2006-09-28
EP1871382B1 (en) 2011-08-17
WO2006102644A2 (en) 2006-09-28
HK1128242A1 (en) 2009-10-23
ATE520404T1 (de) 2011-09-15
EP2030622B1 (en) 2011-02-23
EP1868614B1 (en) 2012-08-08
PT2030622E (pt) 2011-06-02
WO2006102644A3 (en) 2007-03-01
CA2601715A1 (en) 2006-09-28
JP2008534515A (ja) 2008-08-28
EP2030622A1 (en) 2009-03-04
EP1871382A2 (en) 2008-01-02
AU2006226811A1 (en) 2006-09-28
CY1111478T1 (el) 2015-08-05
JP5295755B2 (ja) 2013-09-18
JP2013234191A (ja) 2013-11-21
JP5496407B2 (ja) 2014-05-21
ES2392454T3 (es) 2012-12-10
PL2030622T3 (pl) 2011-07-29
US20090325920A1 (en) 2009-12-31
AU2006226774B2 (en) 2010-12-02
HRP20120688T1 (hr) 2012-09-30
AU2006226811B2 (en) 2010-11-25
CA2602950A1 (en) 2006-09-28
EP2494976A1 (en) 2012-09-05
US20090221544A1 (en) 2009-09-03
JP2014055183A (ja) 2014-03-27
EP2431042B1 (en) 2013-06-26
DK1868614T3 (da) 2012-11-12
US20120289491A1 (en) 2012-11-15
HK1112579A1 (en) 2008-09-12
JP5394059B2 (ja) 2014-01-22
PL1868614T3 (pl) 2013-01-31
US8614203B2 (en) 2013-12-24
EP1868614A2 (en) 2007-12-26

Similar Documents

Publication Publication Date Title
CY1113253T1 (el) Δοσολογικο σχημα για τη θεραπευτικη αντιμετωπιση μιας τραυματικης εγκεφαλικης βλαβης με προγεστερονη
CY1117916T1 (el) Θεραπεια διαταραχων που σχετιζονται me bdnf χρησιμοποιωντας laquinimod
CY1120445T1 (el) Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου
CY1117357T1 (el) Υγρες φαρμακοτεχνικες μορφες για θεραπεια ασθενειων ή καταστασεων
CY1116727T1 (el) Θεραπεια πολλαπλης σκληρυνσης me laquinimod
CY1121288T1 (el) Μεθοδος αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας
WO2008039898A3 (en) Methods for the treatment of a traumatic central nervous system injury
CY1110013T1 (el) Συνδυασμοι για θεραπεια πολλαπλου μυελωματος
CY1110495T1 (el) Χρηση ενος αγωνιστη υποδοχεα nmda για τη θεραπεια εμβοης που προκαλειται απο κοχλιακη διεγερτοτοξικοτητα
JP2006501240A5 (el)
AR070842A1 (es) Regimen de dosificacion para un agonista de receptor selectivo de s1p1
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
JP2013155188A5 (el)
JP2014530873A5 (el)
BR112015003836A2 (pt) sistemas e métodos para distribuição de drogas para tratamento de câncer de bexiga
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
RU2013123646A (ru) Комбинированная композиция
RU2010151660A (ru) Способы лечения множественной миеломы
CY1115269T1 (el) Χρηση ανταγωνιστων οπιοειδων για την παρασκευη ενος φαρμακου στη θεραπευτικη αγωγη εκφυλιστικων ασθενειων του αμφιβληστροειδους
EP3590338A3 (en) Medical treatments based on anamorelin
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
MX2021002090A (es) Metodos para reducir el riesgo de diabetes en pacientes que son tratados por enfermedades relacionadas con el colesterol alto.
NO20024683L (no) Terapier med oppdelte doser som har vaskulirt skadende aktivitet
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
AR111491A1 (es) Métodos para tratar enfermedades pediátricas